Alumis Inc. - SIC # 2836 - BIOLOGICAL PRODUCTS, EXCEPT DIAGNOSTIC SUBSTANCES

Ticker Exchange SIC # Website Latest Ticker
ALMS Nasdaq 2836 www.alumis.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Alumis Inc.

Owning 32% shares,hedge funds owners seem interested in Alumis Inc. (NASDAQ:ALMS), - Dec 28th, 2024 1:27 pm
Alumis Announces Positive Phase 1 Data for CNS Penetrant TYK2 Inhibitor, A-005 - Dec 19th, 2024 1:00 pm
Alumis Presents Data Highlighting ESK-001’s Potential as a High-efficacy Oral Treatment for Systemic Lupus Erythematosus (SLE) at ACR Convergence 2024 - Nov 14th, 2024 9:05 pm
Alumis Reports Third Quarter 2024 Financial Results and Highlights Recent Achievements - Nov 13th, 2024 9:05 pm
Alumis to Participate in Guggenheim's Inaugural Healthcare Innovation Conference - Nov 4th, 2024 1:00 pm
Late-Breaking Data at EADV of ESK-001, an Oral TYK2 Inhibitor for the Treatment of Psoriasis, Demonstrate Significant Responses with Sustained Increases Over 28 Weeks in Phase 2 OLE Study - Sep 27th, 2024 1:00 pm
Alumis to Participate in Upcoming September Investor Conferences - Sep 3rd, 2024 8:29 pm
Alumis Reports Second Quarter 2024 Financial Results and Highlights Recent Development and Corporate Achievements - Aug 13th, 2024 8:05 pm
Alumis Initiates ONWARD Phase 3 Clinical Program Evaluating ESK-001, an Oral TYK2 Inhibitor, in Moderate-to-Severe Plaque Psoriasis - Jul 29th, 2024 12:00 pm
Alumis Announces Pricing of Initial Public Offering - Jun 28th, 2024 3:57 am